Tasly Tianjin Biopharmaceutical Co., Ltd.
3 clinical trials · Sponsor
◉ Watch Tasly Tianjin Biopharmaceutical Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients (NCT04189276) | Tasly Tianjin Biopharmaceutical Co., Ltd. | 2019-12-10 |
| Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors (NCT04226066) | Tasly Tianjin Biopharmaceutical Co., Ltd. | 2019-11-20 |
| Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients (NCT04168333) | Tasly Tianjin Biopharmaceutical Co., Ltd. | 2018-01-08 |
Track Tasly Tianjin Biopharmaceutical Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.